AYTU Overview

Nutex Health's Performance: Nutex Health Inc. saw a significant after-hours surge of 20.97% to $120.00 following a quarterly report that revealed a net loss of $17.7 million but a remarkable 220.7% increase in revenue year-over-year to $244.0 million.

Bullfrog AI Holdings Update: Bullfrog AI Holdings, Inc. gained 5.87% to $0.9798 in after-hours trading, likely due to investor positioning ahead of its upcoming technical presentation at the AI Drug Discovery & Development Summit 2025.

Clearside Biomedical's Recovery: Clearside Biomedical, Inc. rose 6.51% to $3.27 after reporting a narrower net loss of $5.97 million, although its revenue fell sharply to $201 thousand from $1.04 million a year ago.

Aytu BioPharma and OKYO Pharma Developments: Aytu BioPharma, Inc. climbed 8.91% to $2.20 after reporting a first-quarter net income increase, while OKYO Pharma Limited edged up 2.44% to $2.18, preparing for a presentation on its investigational drug candidate for neuropathic corneal pain.

Financial Performance: Aytu BioPharma reported net revenue of $13.9 million for the quarter, driven by a 10% increase in their ADHD portfolio, although overall revenue decreased from the previous year due to a one-time rebate benefit.

Product Launch and Patent Extension: The company is on track to launch its new product, Exua, by the end of 2025, and has successfully extended the Exua method of use patent to September 2030, enhancing its market exclusivity.

Operational Investments: Operating expenses rose to $10.2 million as the company invested in the Exua launch, contributing to a negative adjusted EBITDA of $0.6 million for the quarter.

Market Strategy and Feedback: Aytu is focusing on engaging prescribers for Exua, targeting younger patients dissatisfied with current medications, and expects better coverage from payers compared to its ADHD products.

Milestone Scientific Inc. Earnings: Milestone Scientific's shares rose 36.10% after reporting a third-quarter net loss of $1.2 million, with revenue slightly down to $2.4 million due to weaker domestic dental sales but stronger international demand.

Applied Therapeutics Inc. Update: Applied Therapeutics saw a 14.78% increase in shares after narrowing its Q3 net loss to $19 million and announcing a meeting with the FDA to discuss the regulatory path for govorestat in Classic Galactosemia.

Omeros Corp. Financial Results: Omeros Corp. shares gained 20.54% following a Q3 net loss of $30.9 million, with an update on its Biologics License Application for narsoplimab and an extended FDA action date to December 2025.

The Oncology Institute Inc. Performance: The Oncology Institute's shares rose 19.48% after reporting a 36.7% increase in Q3 revenue to $136.6 million, while also raising its full-year revenue guidance to between $495 million and $505 million.

Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make winning trades in the stock market.

Exclusive Community: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.

Management Insights: Aytu BioPharma's CEO, Joshua Disbrow, highlighted strong financial performance with a net revenue of $66.4 million and an adjusted EBITDA of $9.2 million, while announcing the upcoming launch of EXXUA, a novel treatment for major depressive disorder, which is expected to transform the company’s future.

Launch and Financial Outlook: The EXXUA launch is anticipated in Q4 2025, with a $10 million investment planned for its initial rollout. Management expects minimal revenue in the early quarters post-launch, with significant growth projected into fiscal 2027, while also addressing risks from generic competitors in the ADHD market.